<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796206</url>
  </required_header>
  <id_info>
    <org_study_id>MIL62-CT308</org_study_id>
    <nct_id>NCT05796206</nct_id>
  </id_info>
  <brief_title>A Clinical Study of MIL62 in Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Mabworks Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Mabworks Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, pharmacokinetics(PK) 、pharmacodynamics(PD) and&#xD;
      ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and Part B:Percentage of participants achieving SRI-4 at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Proportion of participants achieving SRI-4 at Week 76</measure>
    <time_frame>Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Percent of patients achieving The British Isles Lupus Assessment Group (BILAG)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Proportion of participants achieving SRI-4 at Week 24.</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Change From Baseline in EuroQol- 5 Dimension (EQ-5D) at Week 52</measure>
    <time_frame>Baseline and Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Change From Baseline in Serum Immunoglobulin Levels at Week 24</measure>
    <time_frame>Baseline and Week 76</time_frame>
    <description>Change from baseline in the serum levels of IgG, IgA, IgM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Change From Baseline in biomarkers associated with disease anti-dsDNA ,complement component 3 (C3), and complement component 4 (C4)</measure>
    <time_frame>Baseline and Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline to Week 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Pharmacokinetic(PK) Parameters: AUC</measure>
    <time_frame>up to Week76Day7 after enrollment</time_frame>
    <description>The area under the curve (AUC) of serum concentration of the drug after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Pharmacokinetic(PK) Parameters:Cmax</measure>
    <time_frame>up to Week76Day7 after enrollment</time_frame>
    <description>Maximum concentration(Cmax) of the drug after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B:Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL62</measure>
    <time_frame>up to Week76Day7 after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>MIL62(Part A and B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A and B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIL62</intervention_name>
    <description>An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.</description>
    <arm_group_label>MIL62(Part A and B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>An intravenous (IV) infusion of placebo will be administered at W1D1、W3D1、W25D1、W27D1、W53D1、W55D1.</description>
    <arm_group_label>Placebo (Part A and B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 ;&#xD;
&#xD;
          2. Diagnosis of systemic lupus erythematosus according to European League Against&#xD;
             Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ;&#xD;
&#xD;
          3. Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ;&#xD;
&#xD;
          4. Low C3 and/or low C4 complement at screening ;&#xD;
&#xD;
          5. High disease activity at screening ;&#xD;
&#xD;
          6. On a stable SLE treatment regimen for at least 30 days prior to the first&#xD;
             administration；&#xD;
&#xD;
          7. Able and willing to provide written informed consent and to comply with the study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unsufficient organ function;&#xD;
&#xD;
          2. Have received treatment with B cell targeted therapy within 9 months prior to the&#xD;
             first administration;&#xD;
&#xD;
          3. Subjects with CD4+ T lymphocyte count &lt; 200 cells/μL;&#xD;
&#xD;
          4. Receipt of any of the following prior to the first administration:&#xD;
             Cyclophosphamide,Calcineurin inhibitor, blood transfusion ;&#xD;
&#xD;
          5. Received TNF inhibitor, Beliumumab, and Tetasercept within 3 months prior to the first&#xD;
             administration; Interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor within 2&#xD;
             months prior to the first administration;&#xD;
&#xD;
          6. Received live or attenuated vaccination within 28 days prior to the first&#xD;
             administration;&#xD;
&#xD;
          7. Participated in other clinical trials within 28 days prior to the first&#xD;
             administration;&#xD;
&#xD;
          8. Concomitant with other serious diseases；&#xD;
&#xD;
          9. Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C;&#xD;
&#xD;
         10. Subjects with known history of severe allergic reactions to humanized monoclonal&#xD;
             antibodies，MIL62；&#xD;
&#xD;
         11. Breastfeeding or pregnant women;&#xD;
&#xD;
         12. Childbearing potential and unwillingness or impossibility to comply with a&#xD;
             scientifically acceptable birth-control method;&#xD;
&#xD;
         13. Other conditions unsuitable for participation in this study determined by the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhanguo Li, Doctor</last_name>
    <phone>(+86)010 -88324172</phone>
    <email>Zgli@aliyun.com</email>
  </overall_contact>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

